Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

New FPP-based inhibitor of protein farnesyltransferase discovered at Banyu

Dec. 15, 1997

Eisai develops novel retinoids as highly potent and selective RXR agonists

Dec. 15, 1997

Genzyme Transgenics' idiotypic vaccines show promise in clinical trials

Dec. 12, 1997

MKT-077: a novel antitumor rhodacyanine dye in clinical testing

Dec. 11, 1997

Profile of novel topoisomerase II inhibitor, ER-37328, from Eisai

Dec. 11, 1997

Protein farnesyltransferase inhibitors focus of research at Merck & Co.

Dec. 11, 1997

ImClone Systems' C225 enters phase II for metastatic renal cell carcinoma

Dec. 11, 1997

SDZ-PSC-833 increases oral bioavailability of paclitaxel

Dec. 10, 1997

Oncologic Drugs Advisory Committee meets next week

Dec. 10, 1997

Preclinical toxicity profile of ISIS-2503

Dec. 9, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...